Department of Medical Mycology, School of Medicine, Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Medical Mycology and Parasitology, Tehran University of Medical Sciences, Tehran, Iran.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02423-17. Print 2018 May.
The objective of this study was to assess the activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanoconazole, terbinafine, itraconazole, and fluconazole) against a large collection of and clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005 μg/ml), followed by lanoconazole (0.002 μg/ml), efinaconazole (0.007 μg/ml), terbinafine (0.011 μg/ml), itraconazole (0.095 μg/ml), and fluconazole (12.77 μg/ml). It appears that efinaconazole, lanoconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to and .
本研究旨在评估新型三唑类抗真菌药物依氟康唑（efinaconazole）以及五种对照药物（卢立康唑、拉康唑、特比萘芬、伊曲康唑和氟康唑）对大量临床和临床分离株的活性。卢立康唑（0.0005μg/ml）的几何平均 MIC 值最低，其次是拉康唑（0.002μg/ml）、依氟康唑（0.007μg/ml）、特比萘芬（0.011μg/ml）、伊曲康唑（0.095μg/ml）和氟康唑（12.77μg/ml）。依氟康唑、拉康唑和卢立康唑似乎是治疗皮肤癣菌病的有前途的候选药物，因为它们对 和 具有活性。
